

Anti-Fungal Treatment Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Pyrimidines), By Therapeutic Indication (Systemic, Candidiasis, Cryptococcosis, Prophylactic Use of Antifungals, Coccidioidomycosis), By Pathogens (Candida, Aspergillus, Cryptococcus, Coccidioides Immitis, Zygomycetes, Trichophyton), By End-Users (Hospitals and Clinics, Dermatology Clinics) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-03-31 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Anti-Fungal Treatment Market Analysis and Insights

The Anti-Fungal Treatment Market size is anticipated to reach USD 18,975.9 Million in 2022 and it is projected to reach USD 33305.42 Million by 2031, growing at a CAGR of % during the forecast period.

The Global Anti-Fungal Treatment Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Anti-Fungal Treatment Market growth, Size report provides a comprehensive analysis of the Healthcare IT industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Experts, Anti-Fungal Treatment Market includes major suppliers & Independent Consultants among others.

Global Market Scope and Anti-Fungal Treatment Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Anti-Fungal Treatment Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Anti-Fungal Treatment Market Country Level Analysis

The Global Anti-Fungal Treatment Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Anti-Fungal Treatment Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Anti-Fungal Treatment Market

Some of the other major highlights of the demand for Anti-Fungal Treatment Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Anti-Fungal Treatment Market during the forecast period.

Pfizer

Astellas Pharma Ltd

Novartis International Ag

Sanofi S.A

Merck KGaA

Bayer Ag

Abbott Laboratories

Janssen Pharmaceuticals

Gilead Sciences, Inc

Cipla Inc.

Market Segmentation

The Global Anti-Fungal Treatment Market Share, Demand provides the most up-to-date Healthcare IT industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Drug Class

Azoles

Echinocandins

Polyenes

Allylamines

Pyrimidines

By Therapeutic Indication

Systemic

Candidiasis

Cryptococcosis

Prophylactic Use of Antifungals

Coccidioidomycosis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

By Pathogens

Candida
Aspergillus
Cryptococcus
Coccidioides Immitis
Zygomycetes
Trichophyton

By End-Users

Hospitals and Clinics
Dermatology Clinics

Regions Coverd

North America

U.S.
Canada

Europe

U.K.
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC

China
Korea
Japan
India
Australia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa

UAE
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM

Brazil
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

- 1 Executive Summary
- 2 Research Scope & Segmentation
 - 2.1 Research Objectives
 - 2.2 Limitations & Assumptions
 - 2.3 Market Scope & Segmentation
 - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
 - 3.1 Emerging Regions / Countries
 - 3.2 Emerging Companies
 - 3.3 Emerging Applications / End Use
- 4 Market Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.1 Drivers
- 4.2 Market Warning Factors
- 4.3 Latest Macro Economic Indicators
- 4.4 Geopolitical Impact
- 4.5 Technology Factors
- 5 Market Assessment
 - 5.1 Porters Five Forces Analysis
 - 5.2 Value Chain Analysis
- 6 Global Anti-Fungal Treatment Market Size Analysis
 - 6.1 By Drug Class
 - 6.1.1 Azoles
 - 6.1.2 Echinocandins
 - 6.1.3 Polyenes
 - 6.1.4 Allylamines
 - 6.1.5 Pyrimidines
 - 6.2 By Therapeutic Indication
 - 6.2.1 Systemic
 - 6.2.2 Candidiasis
 - 6.2.3 Cryptococcosis
 - 6.2.4 Prophylactic Use of Antifungals
 - 6.2.5 Coccidioidomycosis
 - 6.3 By Pathogens
 - 6.3.1 Candida
 - 6.3.2 Aspergillus
 - 6.3.3 Cryptococcus
 - 6.3.4 Coccidioides Immitis
 - 6.3.5 Zygomycetes
 - 6.3.6 Trichophyton
 - 6.4 By End-Users
 - 6.4.1 Hospitals and Clinics
 - 6.4.2 Dermatology Clinics
- 7 North America Market Analysis
 - 7.1 By Drug Class
 - 7.1.1 Azoles
 - 7.1.2 Echinocandins
 - 7.1.3 Polyenes
 - 7.1.4 Allylamines
 - 7.1.5 Pyrimidines
 - 7.2 By Therapeutic Indication
 - 7.2.1 Systemic
 - 7.2.2 Candidiasis
 - 7.2.3 Cryptococcosis
 - 7.2.4 Prophylactic Use of Antifungals
 - 7.2.5 Coccidioidomycosis
 - 7.3 By Pathogens
 - 7.3.1 Candida
 - 7.3.2 Aspergillus

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.3 Cryptococcus
- 7.3.4 Coccidioides Immitis
- 7.3.5 Zygomycetes
- 7.3.6 Trichophyton
- 7.4 By End-Users
 - 7.4.1 Hospitals and Clinics
 - 7.4.2 Dermatology Clinics
- 7.4 U.S.
- 7.5 Canada
- 8 Europe Market Analysis
 - 8.1 By Drug Class
 - 8.1.1 Azoles
 - 8.1.2 Echinocandins
 - 8.1.3 Polyenes
 - 8.1.4 Allylamines
 - 8.1.5 Pyrimidines
 - 8.2 By Therapeutic Indication
 - 8.2.1 Systemic
 - 8.2.2 Candidiasis
 - 8.2.3 Cryptococcosis
 - 8.2.4 Prophylactic Use of Antifungals
 - 8.2.5 Coccidioidomycosis
 - 8.3 By Pathogens
 - 8.3.1 Candida
 - 8.3.2 Aspergillus
 - 8.3.3 Cryptococcus
 - 8.3.4 Coccidioides Immitis
 - 8.3.5 Zygomycetes
 - 8.3.6 Trichophyton
 - 8.4 By End-Users
 - 8.4.1 Hospitals and Clinics
 - 8.4.2 Dermatology Clinics
 - 8.4 U.K.
 - 8.5 Germany
 - 8.6 France
 - 8.7 Spain
 - 8.8 Italy
 - 8.9 Russia
 - 8.10 Nordic
 - 8.11 Benelux
 - 8.12 Rest of Europe
- 9 APAC Market Analysis
 - 9.1 By Drug Class
 - 9.1.1 Azoles
 - 9.1.2 Echinocandins
 - 9.1.3 Polyenes
 - 9.1.4 Allylamines

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1.5 Pyrimidines
- 9.2 By Therapeutic Indication
 - 9.2.1 Systemic
 - 9.2.2 Candidiasis
 - 9.2.3 Cryptococcosis
 - 9.2.4 Prophylactic Use of Antifungals
 - 9.2.5 Coccidioidomycosis
- 9.3 By Pathogens
 - 9.3.1 Candida
 - 9.3.2 Aspergillus
 - 9.3.3 Cryptococcus
 - 9.3.4 Coccidioides Immitis
 - 9.3.5 Zygomycetes
 - 9.3.6 Trichophyton
- 9.4 By End-Users
 - 9.4.1 Hospitals and Clinics
 - 9.4.2 Dermatology Clinics
- 9.4 China
- 9.5 Korea
- 9.6 Japan
- 9.7 India
- 9.8 Australia
- 9.9 Taiwan
- 9.10 South East Asia
- 9.11 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
 - 10.1 By Drug Class
 - 10.1.1 Azoles
 - 10.1.2 Echinocandins
 - 10.1.3 Polyenes
 - 10.1.4 Allylamines
 - 10.1.5 Pyrimidines
 - 10.2 By Therapeutic Indication
 - 10.2.1 Systemic
 - 10.2.2 Candidiasis
 - 10.2.3 Cryptococcosis
 - 10.2.4 Prophylactic Use of Antifungals
 - 10.2.5 Coccidioidomycosis
 - 10.3 By Pathogens
 - 10.3.1 Candida
 - 10.3.2 Aspergillus
 - 10.3.3 Cryptococcus
 - 10.3.4 Coccidioides Immitis
 - 10.3.5 Zygomycetes
 - 10.3.6 Trichophyton
 - 10.4 By End-Users
 - 10.4.1 Hospitals and Clinics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.4.2 Dermatology Clinics
- 10.4 UAE
- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 South Africa
- 10.8 Egypt
- 10.9 Nigeria
- 10.10 Rest of MEA
- 11 LATAM Market Analysis
 - 11.1 By Drug Class
 - 11.1.1 Azoles
 - 11.1.2 Echinocandins
 - 11.1.3 Polyenes
 - 11.1.4 Allylamines
 - 11.1.5 Pyrimidines
 - 11.2 By Therapeutic Indication
 - 11.2.1 Systemic
 - 11.2.2 Candidiasis
 - 11.2.3 Cryptococcosis
 - 11.2.4 Prophylactic Use of Antifungals
 - 11.2.5 Coccidioidomycosis
 - 11.3 By Pathogens
 - 11.3.1 Candida
 - 11.3.2 Aspergillus
 - 11.3.3 Cryptococcus
 - 11.3.4 Coccidioides Immitis
 - 11.3.5 Zygomycetes
 - 11.3.6 Trichophyton
 - 11.4 By End-Users
 - 11.4.1 Hospitals and Clinics
 - 11.4.2 Dermatology Clinics
 - 11.4 Brazil
 - 11.5 Mexico
 - 11.6 Argentina
 - 11.7 Chile
 - 11.8 Colombia
 - 11.9 Rest of LATAM
- 12 Competitive Landscape
 - 12.1 Global Anti-Fungal Treatment Market Share By Players
 - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
 - 13.1 American International Industries (GIGI)
 - 13.1.1 Overview
 - 13.1.2 Business Information
 - 13.1.3 Revenue
 - 13.1.4 ASP
 - 13.1.5 Swot Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1.6 Recent Developments
- 13.2 Astellas Pharma Ltd
- 13.3 Novartis International Ag
- 13.4 Sanofi S.A
- 13.5 Merck KGaA
- 13.6 Bayer Ag
- 13.7 Abbott Laboratories
- 13.8 Janssen Pharmaceuticals
- 13.9 Gilead Sciences, Inc
- 13.10 Cipla Inc.
- 14 Research Methodology
 - 14.1 Research Data
 - 14.1.1 Secondary Data
 - 14.1.1.1 Major secondary sources
 - 14.1.1.2 Key data from secondary sources
 - 14.1.2 Primary Data
 - 14.1.2.1 Key data from primary sources
 - 14.1.2.2 Breakdown of primaries
 - 14.1.3 Secondary And Primary Research
 - 14.1.3.1 Key industry insights
 - 14.2 Market Size Estimation
 - 14.2.1 Bottom-Up Approach
 - 14.2.2 Top-Down Approach
 - 14.2.3 Market Projection
 - 14.3 Research Assumptions
 - 14.3.1 Assumptions
 - 14.4 Limitations
 - 14.5 Risk Assessment
- 15 Appendix
 - 15.1 Discussion Guide
 - 15.2 Customization Options
 - 15.3 Related Reports
- 16 Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Anti-Fungal Treatment Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Pyrimidines), By Therapeutic Indication (Systemic, Candidiasis, Cryptococcosis, Prophylactic Use of Antifungals, Coccidioidomycosis), By Pathogens (Candida, Aspergillus, Cryptococcus, Coccidioides Immitis, Zygomycetes, Trichophyton), By End-Users (Hospitals and Clinics, Dermatology Clinics) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-03-31 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Job title*

Company Name*

Address*

Zip Code*

EU Vat / Tax ID / NIP number*

City*

Country*

Date

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com